Documents

ISR uranium operations, advanced projects, and contract strategy target U.S. supply gap.

Net loss per share widened as extraction fell, but higher uranium sales and advances support future efficiency.

Q1 2026 net income per share rose to $0.03, with strong liquidity and higher uranium extraction.

Leadership shift brings operational focus, M&A drive, and steady uranium market outlook.

ISR uranium operations, strong resource base, and advanced technology drive U.S. growth.

Expanding U.S. uranium production with advanced ISR technology and strong market positioning.

Extraction up 242% year-over-year, liquidity strengthened, and major projects advancing.

Expanding US uranium production with leading ISR operations and a robust growth pipeline.

Higher uranium output, lower costs, and strong liquidity highlight Q3 2025 performance.

Production surged and new projects advanced, setting the stage for strong future growth.

ISR uranium production expands in the U.S. amid rising demand, policy support, and innovation.

Production and efficiency soared, backed by $115M funding and major project expansions.

Net loss per share narrowed, extraction rates rose, and costs fell, supporting ongoing expansion.

Driving U.S. uranium supply growth with advanced ISR operations and strategic project development.

Uranium extraction costs fell, but Q1 net loss rose due to exploration and market losses.

Advancing U.S. uranium production with ISR technology, strong assets, and market-driven growth.

Smooth leadership transition and rapid Alta Mesa production support strong 2025 contract fulfillment.

Revenue up 163% to $58M, but net loss widened on higher costs and compliance expenses.

Revenue growth and dual plant operations position enCore for higher uranium output in 2025.

H1 2024 revenue rose to $36M, with Alta Mesa ramp-up expected to drive further growth.

Operational ISR plants and a strong project pipeline position for major US uranium supply growth.

Production targets rise to 5M lbs/yr by 2028, with market-linked sales through 2032.

FY23 controls were assessed effective amid uranium-market, financing, and execution risks.